Breakthrough Science for Better Health

We are committed to bringing effective medicines with distinct safety and dosing advantages to underserved patients by using the gut as the gateway to better health.
Learn About Us

THE FACTS

740,000 ESRD patients with hyperphosphatemia in major developed countries
~2 Million people in U.S. with CKD and/or heart failure have hyperkalemia
~11 Million people in the U.S. with IBS-C
~90,000 people with ESRD die in the U.S. each year – a number higher than those with breast cancer, hepatitis C and HIV combined
~95% of ESRD patients need phosphate control
Impact

Making Better Medicine For Patients In Need

We are advancing our lead product, tenapanor, for the treatment of hyperphosphatemia in patients with ESRD who are on dialysis, and for patients with IBS-C.

Learn More About Our Tenapanor Programs

“Everyone here is excited about what we’re creating and what it could mean for patients.”

– Kelli, HR

Make An Impact With Us

PIPELINE

PROGRAM
INDICATION
RESEARCH
PHASE 1
PHASE 2
PHASE 3
MARKETED
Gastrointestinal Programs
Tenapanor
IBS-C
(NHE3 Inhibitor)
RDX8940
GI Indications
(TGR5 Agonist)
RDX011
GI Indications
(NHE3 Inhibitor)
RDX023
GI Indications
(FXR Agonist)
Cardiorenal Programs
Tenapanor
ESRD Hyperphosphatemia
(NHE3 Inhibitor)
RDX011
Cardiorenal Indications
(NHE3 Inhibitor)
RDX013
Hyperkalemia
(Potassium Secretagogue)